All In Biotech

Drug Trial Radar · NCT01346592

Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

A Phase III, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety, Tolerability, and Immunogenicity of Fluad and Agriflu Compared to the Non-adjuvanted Trivalent Influenza Vaccine Fluzone in Children 6 to < 72 Months of Age

Last checked: Nov 20, 2026Latest source record: Mar 26, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 6,104 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,104

Actual

Start

Apr 2011

Primary completion

Jul 2012

Study completion Jul 2012

Sponsor

Lead sponsor
Novartis VaccinesNovartis (NVS)
Sponsor type
Industry
First posted
May 3, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Prevention
Who can join
All sexes, from 6 months, up to 72 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Study Aims to Evaluate the Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to \< 72 Months of Age.

Conditions

  • Influenza Disease

Interventions

  • Trivalent split influenza vaccine (TIV)Biological

  • MF59-adjuvanted trivalent influenza vaccine (aTIV)Biological

  • Licensed comparator trivalent split influenza vaccine (comparator TIV)Biological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of Geometric Mean Titers (GMTs) Against Homologous StrainsTime frame: Day 1, Day 50
  2. Comparison of Antibody Responses of aTIV With TIV and Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titers Against Homologous StrainsTime frame: Day 50
  3. Comparison of Antibody Responses of TIV Versus Comparator TIV in Terms of Geometric Mean Titers (GMTs) Against Homologous Strains (6 to <36 Months)Time frame: Day 1, Day 50
  4. Comparison of Antibody Responses of TIV Versus Comparator TIV in Terms of Percentage of Subjects Achieving Seroconversion or ≥4-fold Increase in HI Titer Against Homologous Strains in Subjects 6 to <36 Months of AgeTime frame: Day 50

Locations

34 sites in 5 countries. Site status is shown where the registry gives one.

  • 401 Paideia Jeronimo Salguero 2835 Piso 1

    Buenos Aires, Argentina

  • 402 Hospital de Ninos Gallo 130

    Buenos Aires, Argentina

  • 403 Instituto Medico Rio Cuarto Hipolito Yrigoyen 1020

    Córdoba, Argentina

  • 405 Hospital Pediatrico Nino Jesus Castro Barros 650

    Córdoba, Argentina

  • 406 Hospital Nostra Senora de la Misericordia Belgrano 1500

    Córdoba, Argentina

  • 407 Centro Pediatrico Caballito Directorio 1658

    Cuidad Automa de Beunos Aires, Argentina

  • 408 Centro de Salud 31 Serpa y Republica del Libano

    Mendoza, Argentina

  • 409 Centro de Salud 16 Alpatacal y Chile

    Villa Nueva, Argentina

  • 206 Vaccine and Immunology Research Trials Unit University Department of Paediatrics 2nd floor Clarence Reiger Bldg Womens and Childrens Hospital

    Adelaide, Australia

  • 201 Royal Children Hospital Department of Respiratory Medicine

    Herston, Australia

  • 205 Vaccine and Immunisation Research Group Murdoch Childrens Research Institute School Of Population Health

    Level 5 207 Bouverie Saint, Australia

  • 202 Sydney Children Hospital Department of Immunology and Infectious Diseases

    Randwick, Australia

  • 204 National Centre for Immunisation Research and Surveillance Kids Research Institute The Childrens Hospital at Westmead

    Westmead, Australia

  • 502 Hospital Clinico Pontificia Universidad Catolica de Chile Marcoleta 357

    Santiago, Chile

  • 503 Clinica Tabancura Av Tabancura 1185

    Santiago, Chile

  • 111 DLSHI deCastro De La Salle Health Sciences Institute DBB B Dasmarinas

    Cavite, Philippines

  • 106 Research Institute for Tropical Medicine Alabang Muntinlupa

    City of Muntinlupa, Philippines

  • 108 RITM Research Institute for Tropical Medicine Department of Health Compound FILINVEST Corporate City Alabang

    City of Muntinlupa, Philippines

  • 109 De La Salle Health Sciences Institute

    Dbbb Dasmarinas Cavite, Philippines

  • 110 De La Salle Health Sciences Institute

    Dbbb Dasmarinas Cavite, Philippines

  • 103 Philippine General Hospital Taft Avenue

    Manila, Philippines

  • 107 Philippine General Hospital Taft Avenue

    Manila, Philippines

  • 112 PGH Lim Philippine General Hospital Taft Avenue

    Manila, Philippines

  • 114 Philippine General Hospital Taft Avenue

    Manila, Philippines

  • 105 Mary Chiles General Hospital 667 Gastambide St Sampaloc Manila

    Manila, Philippines

  • 102 University of the East Ramon Magsaysay Memorial 64 Aurora Boulevard Barangay Dona Imelda

    Quezon, Philippines

  • 101 Philippine Childrens Medical Center Quezon Avenue cor Agham Road Quezon City

    Quezon City, Philippines

  • 104 Philippine Childrens Medical Center Quezon Avenue cor Agham Road Quezon City

    Quezon City, Philippines

  • 113 Philippine Childrens Medical Center Quezon Avenue cor Agham Road Quezon City

    Quezon City, Philippines

  • 305 Worthwhile Clinical Trials Lakeview Hospital 1 Mowbray Avenue

    Benoni, South Africa

  • 304 Newgate Centre Suite 3

    Johannesburg, South Africa

  • 303 Emmed Research

    Pretoria, South Africa

  • 301 Perinatal HIV Research Unit, Baragwanath Hospital

    Soweto, South Africa

  • 302 Soweto Clinical Research

    Soweto, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.